|  | Cancer | Skin Cancer

Understanding Cancer Progression: From Tendencies to Malignancy

There is no fixed timeline for malignant transformation. The progression from "malignant tendencies" (dysplasia, carcinoma in situ, clonal expansions) to invasive cancer varies enormously:

  • Cancer type: Pancreatic, SCLC — aggressive (months). Prostate, thyroid (papillary), some breast — indolent (years-decades).
  • Molecular drivers: Mutation burden, genomic instability, specific oncogenes/tumor suppressors.
  • Microenvironment: Immune surveillance, angiogenesis, stroma, microbiome.
  • Host factors: Age, immunity, inflammation, comorbidities, germline genetics.
  • Precursor lesions: Some regress (CIN1, low-grade dysplasia); others inexorably progress (high-grade dysplasia, CIS).

Models

  • Multistep carcinogenesis (Fearon/Vogelstein): Sequential mutations (APC → KRAS → TP53 → SMAD4 in colorectal) over ~10–15 years.
  • Field cancerization: Wide epithelial field primed for multiple independent tumors.
  • Punctuated evolution: Chromothripsis, chromoplexy — catastrophic genomic events accelerate progression.

Clinical Implication

Screening targets detectable preclinical phases (e.g., colonoscopy for adenomas, Pap/HPV for CIN, LDCT for lung nodules). Early interception saves lives.

Skin Cancer - Related Articles